COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00059657
Recruitment Status : Completed
First Posted : May 2, 2003
Last Update Posted : May 19, 2006
Information provided by:
Mitsubishi Tanabe Pharma Corporation

Brief Summary:
Ecraprost in lipid emulsion is being developed for the treatment of Critical leg ischemia (CLI), which is the most severe form of peripheral arterial disease (PAD); This trial is designed to assess the efficacy and safety of the drug in the treatment of CLI.

Condition or disease Intervention/treatment Phase
Peripheral Vascular Disease Drug: Ecraprost in lipid emulsion Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 280 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of CirculaseTM in Conjunction With Peripheral Revascularization for the Treatment of Critical Leg Ischemia
Study Start Date : August 2001
Study Completion Date : November 2005

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Reduction in the proportion of subjects who experience a major amputation.
  2. Reduction in proportion of subjects who die within 6 months from treatment initiation.

Secondary Outcome Measures :
  1. Reduction in major amputation rate only.
  2. Reduction in critical cardiovascular events (MI, stroke, CV death, etc.)
  3. Improvement in graft patency of index operation.
  4. Improvement in complete ulcer healing.
  5. Improvement in pain at rest.
  6. Improvement in quality of life.
  7. Improvement in hemodynamic measurements.
  8. Improvement in neuropathy.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Critical leg ischemia (CLI) defined as distal extremity pain at rest, or peripheral ischemic ulcer(s), with severe hemodynamic impairment as diagnosed by ankle systolic pressure, toe systolic pressure or TcPO2
  • Subjects will already be scheduled to receive a revascularization procedure (e.g., by-pass graft, endovascular procedure, etc.) involving a distal target artery below the knee joint (e.g., below the knee joint popliteal, anterior/posterior tibial, peroneal, plantar, pedal, etc.) as part of their normal standard of care.

Exclusion Criteria:

  • Subjects with a previous major amputation (at or above ankle)
  • Subjects with end stage renal disease (ESRD) defined as significant renal dysfunction evidenced by estimated creatinine clearance of < 20 cc/min, or receiving chronic hemodialysis therapy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00059657

Layout table for location information
United States, Arizona
Phoenix, Arizona, United States
Tucson, Arizona, United States
United States, California
Glendale, California, United States
Los Angeles, California, United States
San Francisco, California, United States
United States, Florida
Pensacola, Florida, United States
United States, Illinois
Springfield, Illinois, United States
United States, Kansas
Shawnee Mission, Kansas, United States
United States, Louisiana
Kenner, Louisiana, United States
United States, Michigan
Royal Oak, Michigan, United States
United States, Mississippi
Biloxi, Mississippi, United States
United States, New York
Rochester, New York, United States
United States, North Carolina
Durham, North Carolina, United States
United States, Texas
San Antonio, Texas, United States
United States, Washington
Tacoma, Washington, United States
United Kingdom
Birmingham, United Kingdom
Bristol, United Kingdom
Dundee, United Kingdom
Hull, United Kingdom
London, United Kingdom
Manchester, United Kingdom
Southhampton, United Kingdom
Sponsors and Collaborators
Mitsubishi Tanabe Pharma Corporation
Layout table for additonal information Identifier: NCT00059657    
Other Study ID Numbers: WFI 01-02
First Posted: May 2, 2003    Key Record Dates
Last Update Posted: May 19, 2006
Last Verified: May 2006
Keywords provided by Mitsubishi Tanabe Pharma Corporation:
Ecraprost in lipid emulsion
peripheral, vascular
Critical Limb Ischemia due to peripheral arterial disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Peripheral Arterial Disease
Peripheral Vascular Diseases
Pathologic Processes
Cardiovascular Diseases
Arterial Occlusive Diseases